Healthcare AI takes another jab to the jaw

Last week a literature review showed none of 62 high-quality medical AI models ready for translation from academic research to clinical practice. Now comes a similar but separate study confirming the depth of the dashed hopes.

Reporting their findings in Science Translational Medicine, the researchers behind the second exercise found just 23% of healthcare machine-learning studies were reproducible with differing datasets.

By comparison, 80% of computer vision studies and 58% of NLP studies had such conceptual reproducibility.

Equally confounding, 55% of machine learning in healthcare papers used public datasets and made their code available. Computer vision and NLP each clocked in at close to 90% on those scores.

IEEE Spectrum takes a quick look at both literature reviews side by side.

“Healthcare is an especially challenging area for machine learning research because many datasets are restricted due to health privacy concerns and even experts may disagree on a diagnosis for a scan or patient,” writes freelance journalist Megan Scudellari. “Still, researchers are optimistic that the field can do better.”

Read the whole thing.

Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.